Galectin Therapeutics
GALT
99 hedge funds and large institutions have $38.8M invested in Galectin Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 15 closing their positions.
1,729% more call options, than puts
Call options by funds: $5.72M | Put options by funds: $313K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3.58% more ownership
Funds ownership: 18.05% → 21.62% (+3.6%)
1% more funds holding
Funds holding: 98 → 99 (+1)
20% less capital invested
Capital invested by funds: $48.1M → $38.8M (-$9.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.88M |
| 2 |
Millennium Management
New York
|
+$1.71M |
| 3 |
Two Sigma Investments
New York
|
+$1.37M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$883K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$818K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$592K |
| 2 |
Morgan Stanley
New York
|
-$532K |
| 3 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$423K |
| 4 |
Goldman Sachs
New York
|
-$373K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$343K |
GALT Hedge Fund Activity: Q1 2026 in Review
99 of the 8,173 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2026, worth a combined $38.8M — down 20% from $48.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new GALT positions and 15 closed out — a net gain of 4 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was Marshall Wace, adding an estimated $1.88M. The largest seller was Wellington Management Group, exiting entirely with an estimated $592K sold.
- 99 institutional investors held Galectin Therapeutics (GALT) as of Q1 2026, up from 98 in Q4 2025.
- Funds reported $38.8M of Galectin Therapeutics stock for Q1 2026, down 20% quarter-over-quarter.
- 19 funds opened new Galectin Therapeutics positions in Q1 2026 and 15 closed out, a net change of +4 holders.
- The largest Galectin Therapeutics buyer in Q1 2026 was Marshall Wace, an estimated $1.88M added.
- The largest Galectin Therapeutics seller in Q1 2026 was Wellington Management Group, an estimated $592K sold.
Based on aggregated 13F filings for Q1 2026.